CoChat

Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection

Open access
Lu, Mei, Li, Jia, Zhang, Talan, Rupp, Loralee B., Trudeau, Sheri, Holmberg, Scott D., Moorman, Anne C., Spradling, Philip R., Teshale, Eyasu H., Xu, Fujie, Boscarino, Joseph A., Schmidt, Mark A., Vijayadeva, Vinutha, Gordon, Stuart C., Holmberg, Scott D., Teshale, Eyasu H., Spradling, Philip R., Moorman, Anne C., Xu, Fujie, Xing, Jim, Tong, Cindy, Gordon, Stuart C., Nerenz, David R., Lu, Mei, Lamerato, Lois, Li, Jia, Rupp, Loralee B., Akkerman, Nonna, Oja-Tebbe, Nancy, Zhang, Talan, Boscarino, Joseph A., Daar, Zahra S., Smith, Robert E., Vijayadeva, Vinutha, Parker, John V., Schmidt, Mark A., Donald, Judy L., Keast, Erin M. · 2016 · Clinical Gastroenterology and Hepatology
Cited by 63

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Sustained virological response (SVR) to antiviral therapy for hepatitis C virus (HCV) correlates with changes in biochemical measures of liver function. However, little is known about the long-term effects of SVR on liver fibrosis. We investigated the effects of HCV therapy on fibrosis, based on the Fibrosis-4 (FIB4) score, over a 10-year period. METHODS We collected data from participants in the Chronic Hepatitis Cohort Study—a large observational multicenter study of patients with hepatitis at 4 US health systems—from January 1, 2006, through December 31, 2013. We calculated patients’ FIB4 score and the aminotransferase-to-platelet ratio index (APRI) score over a 10-year period. Of 4731 patients with HCV infection, 1657 (35%) were treated and 755 (46%) of these patients achieved SVR. RESULTS In propensity score–adjusted analyses, we observed significant longitudinal changes in FIB4 score that varied with treatment and response to treatment. In patients achieving SVR, FIB4 scores decreased sharply, remaining significantly lower over the 10-year period than in untreated patients or patients with treatment failure (P < .001). In independent analyses, men and patients with HCV genotype 1 or 3 infections had higher FIB4 scores than women or patients with HCV genotype 2 infections (P < .01 for both). Findings were similar in a sensitivity analysis that substituted the APRI as the marker of fibrosis instead of the FIB4 score. CONCLUSIONS SVR to HCV treatment appears to induce long-term regression of fibrosis based on FIB4 scores collected over 10 years from a large observational study of US hepatitis patients. Patients receiving no treatment or with treatment failure had progressive increases in FIB4 scores.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2016.01.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Lu, M., Li, J., Zhang, T., Rupp, L. B., Trudeau, S., Holmberg, S. D., Moorman, A. C., Spradling, P. R., Teshale, E. H., Xu, F., Boscarino, J. A., Schmidt, M. A., Vijayadeva, V., Gordon, S. C., Holmberg, S. D., Teshale, E. H., Spradling, P. R., Moorman, A. C., Xu, F., Xing, J., Tong, C., Gordon, S. C., Nerenz, D. R., Lu, M., Lamerato, L., Li, J., Rupp, L. B., Akkerman, N., Oja-Tebbe, N., Zhang, T., Boscarino, J. A., Daar, Z. S., Smith, R. E., Vijayadeva, V., Parker, J. V., Schmidt, M. A., Donald, J. L., & Keast, E. M.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2016-07
Volume
14
Issue
7
Pages
1044-1055.e3
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2288564428
Cited by
63
References
3
FWCI
4.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.